Ligand Pharmaceuticals (LGND) Depreciation & Amortization (CF) (2010 - 2026)

Ligand Pharmaceuticals has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $8.2 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 6.32% year-over-year to $8.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.2 million (down 5.74% YoY) and the FY2025 annual result came in at $33.8 million, down 4.15% from the prior year.
• Depreciation & Amortization (CF) held at $8.2 million in Q1 2026 per LGND's latest filing, from $8.2 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $13.7 million in Q1 2022 and troughed at $8.2 million in Q4 2025.
• A 5-year average of $9.7 million and a median of $8.9 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) climbed 8.67% in 2022, then plunged 36.11% in 2023.
• Over 5 years, Depreciation & Amortization (CF) stood at $11.1 million in 2022, then slipped by 19.93% to $8.9 million in 2023, then decreased by 3.24% to $8.6 million in 2024, then dropped by 4.79% to $8.2 million in 2025, then climbed by 0.02% to $8.2 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $8.2 million, $8.2 million, and $8.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.